AIP
ANIK icon

Ahrens Investment Partners’s Anika Therapeutics ANIK Stock Holding History

Ahrens Investment Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$14.4K Buy
+500
New +$14.9K 0.01% 535
2022
Q3 		– Sell
-500
Closed -$11K – 191
2022
Q2 		$11K Hold
500
– – ﹤0.01% 613
2022
Q1 		$13K Hold
500
– – ﹤0.01% 662
2021
Q4 		$18K Buy
+500
New +$20K 0.01% 595

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ahrens Investment Partners's ANIK Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Anika Therapeutics (ANIK) in Q1 2023: 500 shares worth $14.4K. The stake represents 0.01% of the portfolio and ranks #535 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in ANIK as recently as Q2 2022.

Ahrens Investment Partners first reported a position in ANIK in Q4 2021 and has held it in 4 quarters since. The position peaked at $18K in Q4 2021. 120 funds tracked by Wall St. Rank hold ANIK as of Q1 2023.

  • Ahrens Investment Partners held 500 shares of Anika Therapeutics worth $14.4K as of Q1 2023.
  • Anika Therapeutics was a new Ahrens Investment Partners position in Q1 2023.
  • Anika Therapeutics made up 0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #535 holding.
  • Ahrens Investment Partners first reported a position in Anika Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • Ahrens Investment Partners's Anika Therapeutics position peaked at $18K in Q4 2021.
  • 120 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.